Abstract
The usage of TNF antagonists in patients with hepatitis B virus (HBV) can result in viral reactivation and potential liver failure. However, little is known about the risk of viral reactivation with the newer IL-17 antagonists. We report a patient with seropositive hepatitis B, ankylosing spondylitis, and disabling palmar plantar psoriasis treated successfully with secukinumab without liver complications.
This article is protected by copyright. All rights reserved.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.